The other side of the coin: Leveraging Epstein–Barr virus in research and therapy

Epstein-Barr virus is (EBV) a ubiquitous virus prevalent in 90% of the human population. Transmitted through infected saliva, EBV is the causative agent of infectious mononucleosis (IM) and is further implicated in malignancies of lymphoid and epithelial origins. In the past few decades, research ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Fenggang, Tan, Wei Jian, Lu, Yanan, MacAry, Paul A., Loh, Kwok Seng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108324/
https://www.ncbi.nlm.nih.gov/pubmed/27531881
http://dx.doi.org/10.1016/j.oraloncology.2016.07.010
Descripción
Sumario:Epstein-Barr virus is (EBV) a ubiquitous virus prevalent in 90% of the human population. Transmitted through infected saliva, EBV is the causative agent of infectious mononucleosis (IM) and is further implicated in malignancies of lymphoid and epithelial origins. In the past few decades, research efforts primarily focused on dissecting the mechanism of EBV-induced oncogenesis. Here, we present an alternate facet of the oncovirus EBV, on its applications in research and therapy. Finally, discussions on the prospective utilization of EBV in nasopharyngeal carcinoma (NPC) diagnosis and therapy will also be presented.

Ejemplares similares